Literature DB >> 29651942

An Expedient Synthesis of CMF-019: (S)-5-Methyl-3-{1-(pentan-3-yl)-2- (thiophen-2-ylmethyl)-1H-benzo[d]imidazole-5-carboxamido}hexanoic Acid, a Potent Apelin Receptor (APJ) Agonist.

Lena Trifonov1, Michal Afri1, Krzysztof Palczewski2, Edward E Korshin1, Arie Gruzman1.   

Abstract

BACKGROUND: Apelin receptor (APJ) is a G protein-coupled receptor (GPCR) activated by the endogenous peptide apelin. The apelin-APJ system has emerged as an important regulator of cardiovascular homeostasis. Recently, a potent benzimidazole-derived apelin peptidomimetic, CMF-019, was patented but without a comprehensive description of its synthesis and a complete spectroscopic characterization of the intermediates.
OBJECTIVE: Here, a detailed preparation of CMF-019 through a modified and improved synthetic pathway is described.
METHOD: In particular, the benzimidazole ring in 7 was tailored by the condensation of methyl 3- amino-4-(pentan-3-ylamino)benzoate (4) with (thiophene-2-yl)acetimidate salt 6. Saponification of 7 and the subsequent condensation of the free acid 8 with the corresponding enantiopure β-amino acid methyl ester generated methyl (S)-5-methyl-3-{1-(pentan-3-yl)-2-(thiophen-2-ylmethyl)-1Hbenzo[ d]imidazole-5-carboxamido}hexanoate (9). Hydrolysis of the latter with KOH in THF/water, followed by HPLC-purification, afforded the desired product, CMF-019 (potassium salt) 10. RESULTS &
CONCLUSION: The approach reported herein enables preparation of 10 at a total yield of 12% over seven linear steps. Additionally, it does not require applying expensive designated microwave reactors and high-pressure hydrogenators. Thus, the elaborate synthesis provides a latent availability of potent agonist 10 for further exploring the physiologically essential apelin-APJ system. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  CMF-019; apelin; apelin receptor; benzimidazole scaffold; expedient synthesis; peptidomimetics.

Mesh:

Substances:

Year:  2018        PMID: 29651942     DOI: 10.2174/1573406414666180412154952

Source DB:  PubMed          Journal:  Med Chem        ISSN: 1573-4064            Impact factor:   2.745


  6 in total

1.  Metabolically stable apelin-analogues, incorporating cyclohexylalanine and homoarginine, as potent apelin receptor activators.

Authors:  Kleinberg X Fernandez; Conrad Fischer; Jennie Vu; Mahmoud Gheblawi; Wang Wang; Samantha Gottschalk; Xavier Iturrioz; Catherine Llorens-Cortés; Gavin Y Oudit; John C Vederas
Journal:  RSC Med Chem       Date:  2021-07-08

2.  Identification of potent pyrazole based APELIN receptor (APJ) agonists.

Authors:  Sanju Narayanan; Vineetha Vasukuttan; Sudarshan Rajagopal; Rangan Maitra; Scott P Runyon
Journal:  Bioorg Med Chem       Date:  2019-11-30       Impact factor: 3.641

3.  Rational Alteration of Pharmacokinetics of Chiral Fluorinated and Deuterated Derivatives of Emixustat for Retinal Therapy.

Authors:  Eliav Blum; Jianye Zhang; Jordan Zaluski; David E Einstein; Edward E Korshin; Adam Kubas; Arie Gruzman; Gregory P Tochtrop; Philip D Kiser; Krzysztof Palczewski
Journal:  J Med Chem       Date:  2021-06-03       Impact factor: 8.039

4.  The G Protein Biased Small Molecule Apelin Agonist CMF-019 is Disease Modifying in Endothelial Cell Apoptosis In Vitro and Induces Vasodilatation Without Desensitisation In Vivo.

Authors:  Cai Read; Duuamene Nyimanu; Peiran Yang; Rhoda E Kuc; Thomas L Williams; Christopher M Fitzpatrick; Richard Foster; Robert C Glen; Janet J Maguire; Anthony P Davenport
Journal:  Front Pharmacol       Date:  2021-01-21       Impact factor: 5.810

Review 5.  The Role of Apelin-APJ System in Diabetes and Obesity.

Authors:  Cheng Li; Hongna Cheng; Binay Kumar Adhikari; Shudong Wang; Na Yang; Wenyun Liu; Jian Sun; Yonggang Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-09       Impact factor: 5.555

Review 6.  International Union of Basic and Clinical Pharmacology. CVII. Structure and Pharmacology of the Apelin Receptor with a Recommendation that Elabela/Toddler Is a Second Endogenous Peptide Ligand.

Authors:  Cai Read; Duuamene Nyimanu; Thomas L Williams; David J Huggins; Petra Sulentic; Robyn G C Macrae; Peiran Yang; Robert C Glen; Janet J Maguire; Anthony P Davenport
Journal:  Pharmacol Rev       Date:  2019-10       Impact factor: 25.468

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.